RWA Wealth Partners LLC Takes $238,000 Position in Edwards Lifesciences Co. (NYSE:EW)

RWA Wealth Partners LLC bought a new position in Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 3,120 shares of the medical research company’s stock, valued at approximately $238,000.

A number of other institutional investors also recently bought and sold shares of EW. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its stake in Edwards Lifesciences by 440.0% in the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock worth $243,173,000 after purchasing an additional 2,860,000 shares in the last quarter. AustralianSuper Pty Ltd acquired a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $168,519,000. Nordea Investment Management AB lifted its stake in Edwards Lifesciences by 1,224.1% during the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after acquiring an additional 1,488,791 shares during the period. Wellington Management Group LLP lifted its stake in Edwards Lifesciences by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after acquiring an additional 1,390,427 shares during the period. Finally, FMR LLC lifted its stake in Edwards Lifesciences by 61.1% during the 3rd quarter. FMR LLC now owns 3,111,385 shares of the medical research company’s stock valued at $215,557,000 after acquiring an additional 1,179,637 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on EW. Piper Sandler lifted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research note on Friday. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Wells Fargo & Company lifted their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Finally, Evercore ISI decreased their target price on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research note on Friday. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $93.33.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the transaction, the vice president now owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. In the last quarter, insiders have sold 194,004 shares of company stock valued at $17,166,254. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Down 1.8 %

Shares of EW stock opened at $86.43 on Friday. The company’s 50-day moving average price is $90.28 and its 200-day moving average price is $78.85. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The stock has a market cap of $52.02 billion, a price-to-earnings ratio of 37.58, a PEG ratio of 4.39 and a beta of 1.05. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.